Home / Stocks / Ngl Fine Chem Limited
NGLFINE

Ngl Fine Chem Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,777.0

Change

-71.5 (-2.51%)

Open

₹2,867.1

Prev. Close

₹2,848.5

Day High

₹2,893.4

Day Low

₹2,751.0

Volume Analysis

Traded

4,249

Delivered

2,538

Delivery %

59.73%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (32.9%)
  • •Strong 3-year revenue growth (21.7%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹3,005.66 ₹2,949.53 ₹2,863.26 ₹2,807.13 ₹2,720.86 ₹2,664.73 ₹2,578.46
Fibonacci ₹2,949.53 ₹2,895.13 ₹2,861.53 ₹2,807.13 ₹2,752.73 ₹2,719.13 ₹2,664.73
Camarilla ₹2,816.16 ₹2,803.11 ₹2,790.05 ₹2,807.13 ₹2,763.95 ₹2,750.89 ₹2,737.84

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+98.84%

1 Week

-10.94%

1 Month

+5.85%

3 Months

-5.79%

6 Months

+1.51%

1 Year

+99.53%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹518.81

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

17.53%

Net margin 11.13% × asset turnover 0.88x × equity multiplier 1.79x

Company Overview

Sector

Healthcare

Market Cap

₹1,783 Cr

P/E (TTM)

27.9

ROE

17.4%

Book Value

₹587.0

Face Value

₹5.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Ngl Fine Chem Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 58/100. The strongest factor is Financial Strength (97/100), while Cash Flow (19/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. Strong 3-year EPS growth (32.9%).

TopFund Score — Fundamentals Quality

58/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

97

Growth

67

Valuation

41

Cash Flow

19

Corporate Governance

46

Momentum

69

Institutional Ownership

30

Business Quality

73

Risk & Volatility

57

Liquidity

41

From Screener.in

  • +Company is expected to give good quarter
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 80 88 100 91 93 89 95 104 120 128 149 139 159
Expenses + 66 74 84 81 82 84 89 93 103 105 128 116 131
Operating Profit 14 14 16 9 12 5 6 11 17 22 21 23 28
OPM % 17.0% 16.0% 16.0% 10.0% 12.0% 6.0% 7.0% 11.0% 14.0% 18.0% 14.0% 17.0% 18.0%
Other Income + 3 4 4 6 5 0 -1 6 2 5 2 7 1
Interest 0 0 0 0 0 1 1 1 1 1 1 1 1
Depreciation 3 3 3 3 3 3 3 4 5 5 5 5 7
Profit before tax 14 14 16 12 13 1 1 12 13 21 18 24 22
Tax % 25.0% 30.0% 23.0% 22.0% 26.0% -1.0% 49.0% 22.0% 26.0% 24.0% 24.0% 25.0% 25.0%
Net Profit + 10 10 12 9 10 1 1 9 10 16 13 18 16
EPS in Rs 17 16 20 15 16 2 1 15 16 25 22 30 26
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 18 22 33 28 17 1 -5 15 29 43 57 34 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 88 96 100 114 153 152 258 318 278 339 368 501 575
Expenses + 73 74 74 92 121 130 178 249 243 285 333 421 480
Operating Profit 15 22 25 22 32 22 80 68 35 54 35 80 95
OPM % 17.0% 23.0% 26.0% 19.0% 21.0% 14.0% 31.0% 21.0% 13.0% 16.0% 10.0% 16.0% 17.0%
Other Income + 2 0 1 3 4 1 8 11 6 14 8 8 16
Interest 2 2 1 2 3 3 2 2 2 2 3 5 4
Depreciation 3 3 3 5 6 8 8 10 11 12 12 20 22
Profit before tax 13 18 23 18 28 12 78 67 27 54 28 63 85
Tax % 35.0% 36.0% 35.0% 29.0% 27.0% 31.0% 27.0% 25.0% 25.0% 24.0% 24.0% 24.0% —
Net Profit + 8 11 15 13 20 8 57 50 20 41 21 48 64
EPS in Rs 13 18 24 20 33 14 92 81 33 67 34 78 103
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 5.0% 13.0% 2.0% 2.0% 5.0% 3.0% 5.0% 2.0% —
Sales growth 12 9 4 14 — -1 70 23 -12 22 9 36 41

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 30 41 56 69 89 96 151 200 219 260 279 326 360
Borrowings + 13 14 23 27 27 28 16 30 32 34 78 123 127
Other Liabilities + 21 19 20 31 23 26 36 44 32 59 75 94 138
Total Liabilities 67 78 102 129 142 154 207 277 287 356 435 545 628
Fixed Assets + 17 24 25 56 61 68 64 89 88 86 143 164 291
CWIP 1 2 16 3 0 0 12 6 26 46 50 95 0
Investments 2 3 6 6 9 11 29 29 39 54 60 39 39
Other Assets + 46 49 55 63 73 75 102 153 133 171 183 247 298
Total Assets 67 78 102 129 142 154 207 277 287 356 435 545 628
Equity Capital 3 3 3 3 3 3 3 3 3 3 3 3 3

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 8 8 10 22 9 20 27 14 35 20 32 43
Cash from Investing Activity + -3 -10 -10 -21 -10 -20 -25 -14 -27 -27 -70 -71
Cash from Financing Activity + -4 2 0 0 0 -1 -1 -1 -1 -1 37 30
Net Cash Flow 1 0 0 1 -1 0 2 -1 7 -7 0 2
Free Cash Flow 5 -2 -8 -1 -6 6 10 -15 5 -8 -41 -43
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 80 68 70 128 50 110 60 45 121 62 111 73

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 73.06% → 72.49%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 26.91% 27.16% 27.24% 27.25% 27.23% 27.26% 27.26% 27.26% 27.26% 27.23% 27.43% 27.46%
Promoters 73.06% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.73% 72.49% 72.49%
FII 0.04% 0.1% 0.03% 0.02% 0.05% 0.0% 0.0% 0.0% 0.0% 0.03% 0.05% 0.04%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.02% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Ngl Fine Chem Limited (this stock) 1,783 27.9 4.92 17.4%
Suraksha Diagnostic Ltd 1,780 42.6 6.45 14.2%
Tarsons Products Limited 1,678 205.0 2.65 2.44%
Krsnaa Diagnostics Ltd 1,661 16.9 1.6 10.9%
Syncom Formu (i) Ltd 1,907 20.0 4.06 17.6%
Fischer Medical Venture L 1,642 144.0 3.52 8.91%
Beta Drugs Limited 1,990 38.3 4.54 18.8%

Which Mutual Funds Hold Ngl Fine Chem Limited?

Frequently Asked Questions about Ngl Fine Chem Limited

Community Sentiment

What are other investors saying about Ngl Fine Chem Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.